✦ LIBER ✦

Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies

✍ Scribed by Abdel-Wahab, O.; Klimek, V. M.; Gaskell, A. A.; Viale, A.; Cheng, D.; Kim, E.; Rampal, R.; Bluth, M.; Harding, J. J.; Callahan, M. K.; Merghoub, T.; Berger, M. F.; Solit, D. B.; Rosen, N.; Levine, R. L.; Chapman, P. B.

Book ID: 121800325
Publisher: American Association for Cancer Research
Year: 2014
Tongue: English
Weight: 993 KB
Volume: 4
Category: Article
ISSN: 2159-8274
DOI: 10.1158/2159-8290.CD-13-1038

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MC13-0075 Rapid assessment of TORC1 supp

MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients

✍ Corcoran, R.B.; Rothenberg, M.S.; Piris, A.; Nazarian, R.M.; Maheswaran, S.; Set 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 52 KB

243 Phase 1 (Ph1) Clinical and Pharmacod

243 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors

✍ Bahleda, R.; Zimmer, L.; Garcia, M. Martinez; Dieras, V. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase II study evaluating the efficacy,

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

✍ Mahalingam, Devalingam; Malik, Laeeq; Beeram, Muralidhar; Rodon, Jordi; Sankhala 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 262 KB

413 Phase II study evaluating the effica

413 Phase II study evaluating the efficacy, safety and pharmacodynamic correlative study of dual anti-angiogenic inhibition using Bevacizumab (B) in combination with Sorafenib (S) in patients (pts) with advanced malignant melanoma

✍ D. Mahalingam; M. Beeram; J. Rodon; K. Sankhala; A. Mita; D. Benjamin; J. Michal 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Phase 1b study of safety, tolerability a

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

✍ Mahadevan, Daruka; Sutton, Gregory Ryan; Arteta-Bulos, Rafael; Bowden, Chris J.; 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 747 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB